Bicara Therapeutics BCAX
Bicara Therapeutics Inc. · Nasdaq · Pharmaceutical Preparations
$9.76-44.16%close on Oct. 28, 2026 · volume 15.3M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 8, 2026 | Ryan Cohlhepp President, COO & Interim CEO, director | Sold 10b5-1 plan | 17,500 | $22.90 $22.77-$23.43 | $400,716 |
| Aug. 10, 2026 | Ivan Hyep Chief Financial Officer | Sold 10b5-1 plan | 12,500 | $27.97 | $349,591 |
| Aug. 10, 2026 | Claire Mazumdar Chief Executive Officer, director | Sold 10b5-1 plan | 10,000 | $27.98 | $279,750 |
| Aug. 10, 2026 | Ryan Cohlhepp President and COO, director | Sold 10b5-1 plan | 18,750 | $27.98 | $524,533 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 14 →Entry into a material definitive agreement · Financial statements and exhibits